Contents of this article
The 7th edition of the Phage Therapy Congress world conference on Targeting Phage Therapy is both an in-person and online event, that will be held at the Corinthia Palace in Malta from Thursday 20th June till Friday 21st June 2024.
What is the 7th Targeting Phage Therapy conference and Why attend?
Targeting Phage Therapy 2024 focuses on improving clinical trials by turning research into practice. Robert Schooley, a keynote speaker, will talk about the need for research that can easily move into clinical trials for better results in phage therapy.
The conference will look at new ways to use phage therapy not just for infections, but for other health problems too, hoping to make big improvements in how patients are cared for.
Attendees will learn about the latest innovations, how phages are currently used in medicine, and the challenges and possibilities for their use in the future.
Who will be at the 7th Targeting Phage Therapy conference?
Key global leaders from across the globe will be attending.
Discussions will be held on current issues, what the future might hold, and plans for making phage therapy even better.
Agenda for the 7th Targeting Phage Therapy 2024
Thursday 20th June 2024
Robert T. Schooley from University of California San Diego, USA – Clinical Trials in Phage Therapeutics: Looking Under the Hood
Wolfgang Weninger from Medical University of Vienna, Austria – The Phageome in Normal and Inflamed Human Skin
Jumpei Fujiki from University of California San Diego, USA & Rakuno Gakuen University, Japan – Phage therapy: Targeting intestinal bacterial microbiota for the treatment of Liver disease
Domenico Frezza from University of Roma Tor Vergata, Italy – Towards efficient phage therapies: investigation of phage / bacteria equilibrium with metagenome of dark matter in natural samples
Graham F. Hatfull from University of Pittsburgh, USA – Mycobacteriophages and Their Therapeutic Potential
Paul Turner from Yale University, USA – Leveraging Evolutionary Trade-Offs in Development of Phage Therapy
Frederic Bertels from Max Planck Institute for Evolutionary Biology, Germany – Improving Phages Through Experimental Evolution
Federica Briani from University of Milan, Italy – Addressing Phage Resistance to Enhance the Robustness of Phage Therapy for Pseudomonas aeruginosa Infections in People with Cystic Fibrosis
Antonia P. Sagona from University of Warwick, United Kingdom – Genetic Engineering of Phages to Target Intracellular Bloodstream E.coli Infections
Kilian Vogele from Invitris, Germany – Cell-Free Production of Personalized Therapeutic Phages Targeting Multidrug-Resistant Bacteria
Rodrigo Ibarra Chavez from University of Copenhagen, Denmark – Phage Satellites, a Diversity of Extradimensional Symbionts and Pathways to Phage Therapy
Daria Smalchuk from Germans Trias i Pujol Research Institute, Spain – Efficacy of Mycobacteriophage D29 Against Intracellular Mycobacterium Smegmatis
Sandra Sevilla from Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana, Spain – Bacteriophage-based Cleaning Approaches to Eradicate Salmonella Infantis in Broiler Farms
Marco Pardo-Freire from University of Valencia, Spain – Neutralizing Antibodies After Nebulized Phage Therapy in Cystic Fibrosis Patients
Rostislav Halouzka from MB Pharma, Czech Republic – Strategy for Purification of the Staphylococcus Aureus Bacteriophages
Magdalena Pelka from University of Warsaw, Poland – Development of Phage-based Tool with the Potential to Treat Antibiotic-Resistant Gonorrhea
Monika Adamczyk-Popławska from University of Warsaw, Poland – Phage- Encoded Proteins with Antimicrobial Activity Against Klebsiella Pneumoniae
Jimena Nieto Noblecia from Università Degli Studi Di Milano, Italy – Elucidating Key Steps of Pseudomonas Aeruginosa Infection by DEV Lytic Phage for Phage Therapy
Saija Kiljunen from University of Helsinki, Finland – Phage-antibiotic Combination Therapy Against Recurrent Pseudomonas Septicaemia in a Patient with an Arterial Stent
Semra Tasdurmazli from Yildız Technical University, Turkey – Synergistic Action of RCHAPK With Antibiotics Against MRSA and Its Application in an in Vivo Murine Wound Model
Hande Hancer from Yildız Technical University, Turkey – Antibacterial Activity of Holin Proteins
Friday 21st June 2024
Besarion Lasareishvili from Eliava Institute of Bacteriophage, Microbiology and Virology, Georgia – Modern Concepts of Phage Therapy: An Immunologist’s Vision
Ekaterina Chernevskaya from Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Russia – Adaptive Phage Therapy in The Intensive Care Unit: From Science to Patients
Nannan Wu from Shanghai Public Health Clinical Center, Fudan University, China – Phage Therapy: A Glimpse into Clinical Studies Involving Over 150 Cases
Sabrina Green from KU Leuven, Belgium – Making Antibiotics Great Again: Phage resistance in vivo correlates to resensitivity to antibiotics in panresistant Pseudomonas aeruginosa
Frenk Smrekar CEO of JAFRAL, Slovenia – Production of Phage Products for Various Applications
Farzaneh Moghtader from TiPHAGE San.Tic, Turkey – Hydrogel Beads for Targeted/Controlled Phage Delivery in the Gastrointestinal Tract
Vendula Ficelová from Aumed, Czech Republic – Bacteriophages as Commercial Tools for the Treatment of Civilization Skin Disorders Like Acne or Eczema
Cindy Fevre from Phaxiam Therapeutics, France – Determining the main causes of phage resistance in clinical strains of Pseudomonas aeruginosa
Clara Leandro from Technophage: Investigação E Desenvolvimento Em Biotecnologia S.a., Portugal – Phage Resistance Characterization of a Phage Cocktail Targeting Pseudomonas Aeruginosa Associated to Lung Infections
Antoine Culot from Rime Bioinformatics, France – Bacteriophage Genome Annotation: Comparing Automatic and Manual Approaches
Ivan M. Pchelin from Institute of Experimental Medicine, Russia – Bacteriophage Host Ranges: A Key to the Two Therapy Strategies
Alena Kaltenbrunner from University of Bologna, Italy – Nanobiotechnological Engineering of the M13 Bacteriophage for Targeted Photodynamic Cancer Therapy
Barbara Brenner from Kanzlei BRENNER, Germany – Regulatory restrictions vs. Human Rights, the Hippocratic oath and the Freedom of therapy– The legal aspect of phage therapy
Pieter-Jan Ceyssens from Sciensano, Belgium – Quality control of phage Active Pharmaceutical Ingredients (APIs) in Belgium
Jean-Paul Pirnay from Queen Astrid Military Hospital, Belgium – Magistral Phage Preparations: Is This the Model for Everyone?
View past events by Phage Therapy Congress
